Mecp2 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Mecp2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | Methyl-CpG Binding Protein 2 |
|---|
| Gene | MECP2 |
|---|
| UniProt ID | P51608 |
|---|
| PDB ID | 1QK9, 1IGC, 3C2I |
|---|
| Molecular Weight | 52.4 kDa |
|---|
| Subcellular Localization | Nucleus |
|---|
| Protein Family | Methyl-CpG binding domain (MBD) family |
|---|
MeCP2 is a 52.4 kDa nuclear protein with distinct functional domains:
- Methyl-CpG binding domain (MBD): Residues 78-162, binds methylated DNA
- Transcriptional repression domain (TRD): Residues 207-310
- N-terminal domain: Involved in protein interactions
- C-terminal domain: Contains a transcriptional repressor domain
The protein can bind to:
- Methylated CpG dinucleotides
- Unmethylated DNA via A/T-rich sequences
- Various transcriptional co-repressors
MeCP2 is a transcriptional repressor and regulator that plays critical roles in neuronal development and function:
Primary functions:
- Binds methylated DNA and recruits transcriptional co-repressors
- Modulates chromatin structure
- Regulates gene expression essential for neuronal maturation
- Involved in synaptic plasticity
- Regulates RNA splicing
Target genes:
- Brain-derived neurotrophic factor (BDNF)
- Neurotrophin-3 (NTF3)
- Various neuronal genes
Expression:
- Highly expressed in post-mitotic neurons
- Low expression in glia
- Increased expression during neuronal maturation
- Primary cause: MECP2 loss-of-function mutations cause 95% of Rett syndrome cases
- Neuropathology:
- Reduced brain volume (microcephaly)
- Dendritic atrophy
- Synaptic dysfunction
- Impaired neuronal maturation
- Phenotype: Severe neurodevelopmental disorder with regression
- MECP2 gene duplication causes X-linked intellectual disability
- Features include:
- Intellectual disability
- Autism
- Motor dysfunction
- Premature death (typically in males)
- MeCP2 expression is altered in AD brain
- May interact with amyloid pathology
- Role in neuroinflammation
- MeCP2 dysfunction may contribute to dopaminergic neuron vulnerability
- Altered MeCP2 methylation in PD
- AAV-mediated MECP2 delivery to neurons (careful dosing required due to toxicity)
- CRISPR-based approaches to correct mutations
- BDNF mimetics to compensate for reduced BDNF signaling
- Histone deacetylase (HDAC) inhibitors
- Targeting specific symptoms (seizures, breathing abnormalities)
-
Amir RE, et al. (1999). "Rett syndrome is caused by mutations in X-linked MECP2." Nat Genet. 23(2):185-188. DOI:10.1038/13810
-
Guy J, et al. (2001). "A candidate mouse model for Rett syndrome." Nature. 413(6855):473-475.
-
Chahrour M, et al. (2008). "MeCP2, a key contributor to neurological disease, activates and represses transcription." Science. 320(5880):1224-1229.
Mecp2 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Mecp2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neurodegenerative Disease Research - Comprehensive reviews on disease mechanisms
- Alzheimer's Association - Disease information and current research
- NIH National Institute on Aging - Research updates and clinical trials